you, results, are beginning under results presented Chip, in our study and the in available our to imetelstat good Phase Presentation. the Thank January proud X and afternoon on our We IR were conference January. on to website thrilled line call, everyone IMerge MDS which On and safety detailed of of positive lower-risk the of section efficacy very top we call. report from
summary imetelstat-treated believe we positive imetelstat. arm. meaningful We a control a compared benefit/risk the will placebo high-level of significant in those the I saw statistically overall Today, which improvements to patients clinically results, provide and confirms for profile
Specifically, the TI met XX-week secondary endpoint. its trial endpoint as well of primary a transfusion X-week independence as
in We transfusions. levels reductions and saw in both increases substantial hemoglobin
We also category. and efficacy MDS and saw initial The potential less consistent molecular with frequent modification. events with And both the transfusion evidence the were and safety we RS+ than and adverse which neutropenia clinical disease results resolved patients majority imetelstat’s were subtypes, or reversible prior most in support including across imetelstat’s IPSS reported clinical and being MDS weeks. manageable risk RS- baseline thrombocytopenia, The irrespective burden of X were experience. for
were cytopenias low rates imetelstat Importantly, treatment were to with observed consequences similar at these any and serious clinical placebo. from
analyses data providers. we publish opinion results the XXXX with prepare throughout to have with We collaborating and top discussing these are and leaders planning additional been IMerge present key and from to abstracts line as
lower-risk as acknowledgment as received well excellent readout a on MDS. represent to imetelstat on advance the in feedback have treatment We for potential the meaningful
strategy CMC on the this was these line quarter. granted, by of modules, an to rolling participated Based mid-XXXX. from showstoppers module this we When non-clinical results top including our the on continue timeline our the IMerge There at our plan meeting in request request for were Since we we meeting, our on our expected priority quarter, to we the allowed have submit submitted clinical submission. NDA submit change submission the We to to as Phase that under in no the comments expect U.S. review remain the NDA, imetelstat with or X, positive mid-year. a first we track pre-NDA could launch of Also nor execute quarter If commercial for of fundamental as early we Fast XXXX. of submit plan in as the NDA and remaining lower-risk MDS NDA occur approval designation standard MDS. with the FDA. Track granted, lower-risk that plan in and FDA NDA
of timing. by unless addition, interactions, up is MAA we XX forward, provide review our the MAA planned of or change XXXX. to months. we expect of time submission for is potential the Please Thus, Typically, to end regulatory a they submission approval relating XXXX. going the the any by result end MAA In the an to strategy the expected don’t to timing details plan in of note,
analysis this each Moving are trigger to whether Phase is of event-driven, analysis occur. interim could me Thus, on and of around required events of the XXX for the interim total trial enrollment expect conduct assumptions. in XXXX events period. only the patients and overall before study need for These will survival for complete XXXX. median OS with to than to interim patients. these enrollment as enrollment IMpactMF number at timing our MF. X first enrollment interim death our clinical is of as planned the treatment program, in enrolled for occur the enrollment as this will X planning occur well which analysis study, and occur reflect death death rate number current on we to analyses the Potentially, IMpactMF as current endpoint. is second analysis Using plans actual the estimates rates Phase outline MF the relapsed/refractory for throughout in it and accrue events assumptions arm, events the primary let for To the death the depends events the more of XX% uncertain
recruitment quarter, This investigators strategies meetings. patient enrollment, interactions rate more medical and site visits initiated for with of we patient and engagement increase including initiatives on-site at or matching several the activation through to
consider initiatives enrollment will next the of as rates study. of the and We well events over X the these evaluate overall months in occurring as the death impact
an analysis interim of that the update on expect timing provide projected We the after to evaluation.
be likely trial, patients MF, confirmed X X from relapsed/refractory approved treatment in the and can Phase will improvement OS other we in in differentiated patients. Phase observed in be currently paradigm will IMpactMF development strongly IMbark imetelstat-treated MF the believe the treatments and trial that or change imetelstat our in If in was for
personal ultimate As measure patients. know physicians consider of OS that their I of for the benefit from experience cancer a treatment as hematologist, the
options treatment patients would to need IMpactMF limited expect JAK their no case therapy. longer are who, We dismal for desperate and of who respond in due in OS novel the to prognosis be current especially relevant inhibitors and
Beyond to a preclinical we with stem from the design our X of several in activity sequential trials, programs ruxolitinib a imetelstat X have in was potentially informed additional imetelstat started in hematologic This studies, to malignancies. evaluate cells Phase inhibitory May MF. imetelstat followed the study data we frontline designed IMproveMF, Phase malignant expand describing for hematopoietic by by stem applications has the treatment safety with of the and clinical MF combination normal selective XXXX, effect cells. study patients on of ruxolitinib sparring treatment In
profile what frontline treatment imetelstat Phase site trial sites open patient imetelstat population. as in X for with potential in a for we open the in setting, three of Two study determine to expected for safety of IMproveMF, any patient relapsed/refractory was the For trial ruxolitinib enrollment of and enrollment remaining activity are MF this to similar explore is to the XXXX. regimen a disease combination disease-modifying the IMbark in observed for well as aim the myelofibrosis
data We the XXXX. from to also study end present expect preliminary this of by
survival stem a prolonged higher-risk AML models also already for investigator-led hypomethylating Based expansion leukemic on and are we treated human study imetelstat showing preclinical in stem AML in patients with agent. relapsed/refractory MDS of supporting cells, an prevented cells are and who
study a treatment this this evaluating is severe imetelstat disease. noted slide, called the in as As on IMpress, single-agent
drugs initial to patients. AML, and expect MDS part open promise that planned study, in the the are IMpress higher-risk If is of imetelstat in The for imetelstat combination care evaluating XXXX. of such first for another support standard site data other the show plus of investigator-led to we
data published programs. lymphoid provides early imetelstat next-generation of next-generation assess program our from these our of preclinical November we and a a was of the our This to lead oral on being in telomerase at by Center. Moving research malignancies malignancies the TI and snapshot inhibitor. early effect the as pre-clinical slide in In lymphoid compound conducted programs potential continuing status expect of therapeutic malignancies lymphoid programs. XXXX, and on MD Cancer collaboration The a further objective potential results, Anderson the data Based end identify are is discovery to XXXX. the of to
investigate continue as entities potential scaffolds. to We chemical various
We completion effort an of any of next expect advance potentially successful, in studies upon of the research. into discovery would IND-enabling XXXX, which in the to future. efforts step of the current non-clinical discovery initiation these plan we If permit compounds these
you many explore hope of in results imetelstat I provided patients. described, other and MF, how lymphoid for and relapsed/refractory AML, MF, frontline provide benefit We we see I may to the higher-risk will next-generation MDS As can the positive such discovery topline the malignancies inhibition as in imetelstat’s inhibitors, MDS telomerase and more believe next potential impetus telomerase potential areas the have in an continued step lower-risk progress development.
will activities around the to commercial of the With Anil? that, to over planned launch I describe call potential imetelstat. turn Anil
